Linear Diagnostics is developing a rapid diagnostic platform based on a novel application of linear dichroism. The technology uses polarized light to measure the alignment of detector molecules, allowing identification of bacteria, proteins, and genes and providing quantitative readings from a single sample. The company plans to develop the platform into a handheld device that detects bacterial infections and simultaneously identifies the risk of resistance to commonly prescribed antibiotics without laboratory facilities. Its first application will be a point-of-care urinary tract infection (UTI) device for use in primary and secondary care to help restrict inappropriate prescriptions and combat antimicrobial resistance. Although initially focused on the medical sector, the platform can also address markets in agri-food, veterinary, and defence settings. Financially, Linear raised £300K in funding supported by an investment from Rainbow Seed Fund and a matching award from the University of Birmingham’s Spinout Investment Fund.

Total raised

$0M

Funding rounds

1

Latest round

Equity

Latest activity

May 2017